OpGen - Spezialist gegen antibiotikaresistente Infektionen (Seite 13)
eröffnet am 13.08.15 09:48:54 von
neuester Beitrag 10.11.23 14:21:39 von
neuester Beitrag 10.11.23 14:21:39 von
Beiträge: 402
ID: 1.217.076
ID: 1.217.076
Aufrufe heute: 0
Gesamt: 36.933
Gesamt: 36.933
Aktive User: 0
ISIN: US68373L4068 · WKN: A3D38S · Symbol: 650
0,4620
EUR
0,00 %
0,0000 EUR
Letzter Kurs 26.04.24 Stuttgart
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 0,5922 | +44,44 | |
| 6,8660 | +44,27 | |
| 11,690 | +40,84 | |
| 0,7000 | +36,69 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,6900 | -14,50 | |
| 2,8150 | -15,21 | |
| 7,6100 | -17,20 | |
| 1,6100 | -18,27 | |
| 2,1200 | -21,77 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 64.937.553 von Erdman am 31.08.20 14:38:18Cash position:
• June 30, 2020–$12.9 million
• Cash raised via ATM and warrant exercises through June 2020 –$20.1 million
• ATM gross capacity -$3.7 million
• ATM gross capacity reset for another $ 6.4 million
• EUR 5 million tranche in non-dilutive debt financing for COVID-19 related R&D from the European Investment Bank (EIB)
• Warrants outstanding –1,033k (864k at average price of $2.16)
• Cash Burn –estimated to be approximately $5.0-$6.0 million per quarter
Capital Structure -Shares Outstanding
• Common Stock –17,693,932
• Warrants –1,033,386 (864,000 warrants avg. exercise price $2.16)
• Convertible –311,003
• Equity Awards –152,189
• Fully Diluted Shares Outstanding –19,190,510
Das sieht so erfreulich gar nicht aus.
Und der Vertrieb läuft über andere Firmen. Die machen dann den Reibach, wenn der Absatz steigt.
Eine offene Frage bleibt, in wie weit das Management Interessen in den Vertriebsfirmen hat.
• June 30, 2020–$12.9 million
• Cash raised via ATM and warrant exercises through June 2020 –$20.1 million
• ATM gross capacity -$3.7 million
• ATM gross capacity reset for another $ 6.4 million
• EUR 5 million tranche in non-dilutive debt financing for COVID-19 related R&D from the European Investment Bank (EIB)
• Warrants outstanding –1,033k (864k at average price of $2.16)
• Cash Burn –estimated to be approximately $5.0-$6.0 million per quarter
Capital Structure -Shares Outstanding
• Common Stock –17,693,932
• Warrants –1,033,386 (864,000 warrants avg. exercise price $2.16)
• Convertible –311,003
• Equity Awards –152,189
• Fully Diluted Shares Outstanding –19,190,510
Das sieht so erfreulich gar nicht aus.
Und der Vertrieb läuft über andere Firmen. Die machen dann den Reibach, wenn der Absatz steigt.
Eine offene Frage bleibt, in wie weit das Management Interessen in den Vertriebsfirmen hat.
Antwort auf Beitrag Nr.: 65.212.255 von J_C66 am 28.09.20 14:13:36Na Gott sei Dank, OPGN "atmen" noch...
Bin gespannt auf der heutigen Reaktion Stateside
Bin gespannt auf der heutigen Reaktion Stateside
Hab ich was verpasst oder ist das ein neues Offering!?
Trading Spotlight
Alter Wein in neuen Schläuchen?
OpGen Reports Second Quarter 2020 Financial Results and Provides Business Update
08.12.20
- Total Revenue for Q2 2020 was approximately $1.2 million dollars
- Balance sheet strengthened significantly with $6.1 million cash raised in Q2 2020
Strategic co-promotion partnership with Menarini Silicon Biosystems to market
and sell Menarini’s COVID-19 related products
http://ir.opgen.com/news-releases/news-release-details/opgen…
08.12.20
- Total Revenue for Q2 2020 was approximately $1.2 million dollars
- Balance sheet strengthened significantly with $6.1 million cash raised in Q2 2020
Strategic co-promotion partnership with Menarini Silicon Biosystems to market
and sell Menarini’s COVID-19 related products
http://ir.opgen.com/news-releases/news-release-details/opgen…
Antwort auf Beitrag Nr.: 64.937.424 von Erdman am 31.08.20 14:27:16OpGen subsidiary Curetis GmbH has obtained the CE mark certification in the European Union for its own SARS-CoV-2 Kit with PULB for the detection of SARS-CoV-2, the virus that causes COVID-19.
http://ir.opgen.com/news-releases/news-release-details/opgen…
http://ir.opgen.com/news-releases/news-release-details/opgen…
OpGen Announces CE-IVD Marking and Commercial Launch in Europe of its Own Developed Molecular Diagnostic SARS-CoV-2 Kit with PULB for Detection of the Virus Causing COVID-19
- Own developed SARS-CoV-2 Kit with PULB for COVID-19 uses real-time PCR (RT-PCR) technology on open PCR platforms, designed to provide results in approximately one hour
- 100% Sensitivity and 97.3% Specificity demonstrated in isolated RNA
- Inclusion of PCR-Compatible Universal Lysis Buffer (PULB) in the kit as a workflow option allows labs to circumvent the need for extraction equipment and reagents
- Own developed SARS-CoV-2 Kit with PULB for COVID-19 uses real-time PCR (RT-PCR) technology on open PCR platforms, designed to provide results in approximately one hour
- 100% Sensitivity and 97.3% Specificity demonstrated in isolated RNA
- Inclusion of PCR-Compatible Universal Lysis Buffer (PULB) in the kit as a workflow option allows labs to circumvent the need for extraction equipment and reagents
Antwort auf Beitrag Nr.: 64.900.073 von digerdiga am 27.08.20 12:30:09Kann mich an kein prognostiziertes Kursziel meinerseits erinnern. Im Zweifelsfall kein astronomisches. Gebe so gut wie nie Kursprognosen ab und schon gar nicht bei Biowerten.
Durchsuchen
